Results 221 to 230 of about 39,021 (326)

Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications

, 2017
Andrew W. Hahn, David Gill, Benjamin L. Maughan, Archana Agarwal, Lubina Arjyal, Sumati Gupta, Jessica Streeter, Erin Bailey, Sumanta K. Pal, Neeraj Agarwal   +9 more
openalex   +2 more sources

Synthetic lethality in cancer therapy: Mechanisms, models and clinical translation for overcoming therapeutic resistance

Clinical and Translational Medicine, Volume 16, Issue 1, January 2026.
Application of synthetic lethality screening in drug resistance models. Abstract Background and Rationale Synthetic lethality (SL)‐based strategies hold significant promise for overcoming therapeutic resistance, a critical bottleneck in cancer treatment where cancer cells evade anticancer therapies, leading to diminished efficacy or treatment failure ...
Junyan Li, Liyuan Zhang, Yan Shang, Juan Liu, Hailong Zhao   +4 more
wiley   +1 more source

Generic Protocols for Analytical Validation of Tumor-Informed Circulating Tumor DNA Assays for Molecular Residual Disease: The Blood Profiling Atlas in Cancer's Molecular Residual Disease Analytical Validation Working Group Consensus Recommendation. [PDF]

JCO Precis Oncol
Baden J, Lin CJ, Anfora AT, Beer J, Bisselou K, Bungo J, Corner AS, Danek T, Dickey J, Godsey JH, Johann DJ, Jones G, Karlin-Neumann G, Larson JL, Lee JSH, Liu L, Lopez Ramos D, Merriam D, Palomares M, Pena CE, Rathbun J, Rhodes K, Connolly Rohrbach JE, Saritas-Yildirim B, Sausen M, Zhang S, Leiman LC.   +26 more
europepmc   +1 more source

Whole-exome tumor-agnostic ctDNA analysis enhances minimal residual disease detection and reveals relapse mechanisms in localized colon cancer [PDF]

Jorge Martín-Arana, Francisco Gimeno-Valiente, Tenna Vesterman Henriksen, Blanca García-Micó, B. Martínez-Castedo, Valentina Gambardella, Carolina Martínez‐Ciarpaglini, Brenda Palomar-De Lucas, Marisol Huerta, Daniel G. Camblor, M. Bartolomé, Juan Antonio Carbonell‐Asins, Amanda Frydendahl, Kåre Andersson Gotschalck, Tania Fleitas, R. Tébar-Martínez, D Moro, Vicente Pla, Leticia Pérez‐Santiago, José Martín‐Arévalo, David Casado, Stephanie García‐Botello, Alejandro Espí, Susana Roselló, Desamparados Roda, Claus L. Andersen, Andrés Cervantes, Noelia Tarazona   +27 more
openalex   +1 more source

Data from Quantification of Translocation-Specific ctDNA Provides an Integrating Parameter for Early Assessment of Treatment Response and Risk Stratification in Ewing Sarcoma

, 2023
Manuela Krumbholz, Johanna Eiblwieser, Andreas Ranft, Jakob Zierk, Christian Schmidkonz, Adrian M. Stütz, Peter Peneder, Eleni M. Tomazou, Abbas Agaimy, Tobias Bäuerle, Wolfgang Hartmann, Uta Dirksen, Markus Metzler   +12 more
openalex   +1 more source

Synergistic Strategies in Systemic Therapy for Advanced Hepatocellular Carcinoma

Global Challenges, Volume 10, Issue 1, January 2026.
This article comprehensively examines the evolving landscape of systemic therapy for advanced hepatocellular carcinoma. It covers the progress in tyrosine kinase inhibitors and immune checkpoint inhibitors, analyzes the efficacy of novel combination strategies, and discusses current challenges like drug resistance and the lack of biomarkers.
Yongxin Yu, Yulang Jiang, Yipeng Yang, Christian Glandorff, Wenzheng Fang, Mingyu Sun   +5 more
wiley   +1 more source

Circulating tumor DNA as prognostic markers of non-small cell lung cancer (NSCLC): a systematic review and meta-analysis. [PDF]

Transl Lung Cancer Res
Chen X, Zhang M, Zhou Q, Guo N, Cao B, Zeng H, Chen W, Sun F.   +7 more
europepmc   +1 more source

Supplementary Table 1 from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer

Carmela Ciardullo, Luis Tobalina, T. Hedley Carr, Philip Szekeres, Silvija Kraljevic, Lauren A. Byers, Giulia Fabbri   +6 more
openalex   +1 more source

Molecular profiling of tumour and ctDNA in a gastrointestinal cancer cohort at an academic cancer centre [PDF]

, 2018
Samuel Rack, Gerard Brady, Andrew J. Wallace, Melanie Galvin, Kristopher K. Frese, Matthew Krebs, Caroline Dive, Dominic G. Rothwell, Mahmood Ayub, Natalie Cook   +9 more
openalex   +1 more source

Triplet regimens for frontline treatment of CLL—Great company or just a crowd?

HemaSphere, Volume 10, Issue 1, January 2026.
Abstract Standard frontline treatment of chronic lymphocytic leukemia (CLL) is with fixed‐duration venetoclax‐based doublets or indefinite covalent Bruton tyrosine kinase inhibitor (BTKI). Although these approaches achieve excellent results, venetoclax doublets have diminished efficacy in high‐risk biological subgroups, and indefinite covalent Bruton ...
Sean McKeague, John F. Seymour
wiley   +1 more source